Publications by authors named "Necmi Eren"

Background: B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) play key roles in the pathogenesis of IgA nephropathy. Atacicept is a novel fully humanized fusion protein, self-administered at home by subcutaneous injection, that binds and inhibits BAFF and APRIL. By inhibiting BAFF and APRIL, atacicept targets the underlying B-cell–mediated pathogenesis driving disease progression.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the prognostic factors for C3 glomerulopathy (C3G), focusing on the total chronicity score (TCS) derived from a new histological index (C3G-HI).
  • 74 patients from 20 medical centers were analyzed to determine factors affecting kidney health outcomes, with a particular emphasis on hemoglobin levels and their correlation with patient survival and kidney function.
  • Results indicated that low hemoglobin levels were linked to worse outcomes in C3G patients, and a TCS of 4 or higher correlated with significantly lower kidney survival rates over three years.
View Article and Find Full Text PDF

Background: We evaluated the efficacy of different immunosuppressive regimens in patients with primary membranous nephropathy in a large national cohort.

Methods: In this registry study, 558 patients from 47 centers who were treated with at least one immunosuppressive agent and had adequate follow-up data were included. Primary outcome was defined as complete (CR) or partial remission (PR).

View Article and Find Full Text PDF

Aim: BK polyomavirus infection is a challenging complication of renal transplantation. The management is not standardized and is based on reports from transplantation centers' experiences, usually with small sample sizes. Therefore, we aimed to present our countrywide experience with BK virus nephropathy (BKVN) in renal transplant recipients.

View Article and Find Full Text PDF

Background: Immunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate IST results among IgAN patients in Turkiye.

View Article and Find Full Text PDF

Atacicept is a first-in-class, dual anti-B-cell Activation Factor-A Proliferation-Inducing Ligand fusion protein in clinical evaluation for treatment of IgA nephropathy. To compare efficacy and safety of atacicept versus placebo in patients with IgAN, this randomized, double-blind, placebo-controlled phase 2b clinical trial ORIGIN enrolled 116 individuals with biopsy-proven IgA nephropathy. Participants were randomized to atacicept 150, 75, or 25 mg versus placebo once weekly for up to 36 weeks.

View Article and Find Full Text PDF
Article Synopsis
  • The study looks at primary FSGS (pFSGS) in Turkey and compares it to trends in other countries, noting that pFSGS cases are rising in the USA but not in Europe or Asia.
  • Researchers used data from Turkish patients with confirmed pFSGS, finding that many are men around 40 years old, with most experiencing nephrotic syndrome as the main symptom.
  • Key findings show that many patients have specific kidney issues, with differences between males and females in blood pressure and kidney function, while overall cases of pFSGS remain stable in Turkey.
View Article and Find Full Text PDF

Background: Immunoglobulin A nephropathy (IgAN) is a common primary glomerulonephropathy. There is evidence that mesangial C3 deposition plays a role in the development of the disease. The aim of this study was to examine the effect of C3 deposition on the prognosis of IgAN patients.

View Article and Find Full Text PDF

Background: IgA nephropathy is a chronic immune-mediated kidney disease and a major cause of kidney failure worldwide. The gut mucosal immune system is implicated in its pathogenesis, and Nefecon is a novel, oral, targeted-release formulation of budesonide designed to act at the gut mucosal level. We present findings from the 2-year, phase 3 NefIgArd trial of Nefecon in patients with IgA nephropathy.

View Article and Find Full Text PDF

Introduction: With increased fluid intake and tolvaptan treatment, the growth rate of cysts can be theoretically decelerated in autosomal polycystic kidney disease. In this prospective study, it was planned to evaluate thirst sensation in these patients and the parameters affecting its intensity.

Methods: Forty-one ADPKD patients on tolvaptan and 40 ADPKD patients not on tolvaptan as the control group were evaluated for thirst distress sensation and intensity.

View Article and Find Full Text PDF

Background: Data on antibody response following COVID-19 in kidney transplant recipients is scarce. This crosssectional study aims to investigate the antibody response to COVID-19 among kidney transplant recipients.

Methods: We recruited 46 kidney transplant recipients with RT-PCR-confirmed COVID-19 and 45 recipients without COVID-19 history.

View Article and Find Full Text PDF

Introduction: Data regarding inactivated vaccines for SARS-CoV-2 in patients undergoing maintenance hemodialysis (MHD) are limited. We aimed to investigate humoral responses induced by CoronaVac compared to BNT162b2 in this population.

Methods: In this multicenter prospective cohort study, adult patients undergoing MHD who lacked a history of COVID-19 and decided to get vaccinated with BNT162b2 or CoronaVac were enrolled.

View Article and Find Full Text PDF

The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase 2b NEFIGAN trial. To verify these findings, the phase 3 NefigArd trial tested the efficacy and safety of nine months of treatment with Nefecon (16 mg/d) versus placebo in adult patients with primary IgAN at risk of progressing to kidney failure (ClinicalTrials.gov: NCT03643965).

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare clinical outcomes between peritoneal dialysis (PD) patients who had COVID-19 and a control group of PD patients without COVID-19, as there was limited data on this topic.
  • The research involved 223 patients (113 with COVID-19 and 110 controls) and found that while general characteristics were similar, the COVID-19 group had lower serum albumin and hemoglobin levels and more complications like respiratory symptoms and rehospitalization on day 28.
  • Over a 90-day period, mortality rates were low (1 death in the COVID-19 group), and although some health issues persisted for patients who had COVID-19, overall mortality did not significantly differ from the control group.
View Article and Find Full Text PDF

Background: We aimed to evaluate the features of primary membranous nephropathy (MNP) in Turkish people.

Methods: This is a retrospective analysis of patients with biopsy-proven primary MNP. We obtained the data collected between 2009 and 2019 in the primary glomerulonephritis registry of the Turkish Society of Nephrology Glomerular Diseases Study Group (TSN-GOLD).

View Article and Find Full Text PDF

Multiple myeloma is the plasma cell malignancy in which bone involvement is common. The Fibroblast growth factor-23 (FGF-23)/Klotho pathway plays a major role in mineral metabolism that FGF-23 is mineralization inhibitory. Klotho also has anti-apoptotic and anti-tumor effects by acting as a tumor suppressor gene.

View Article and Find Full Text PDF

It is not known whether hearing disorders improves with kidney transplantation. One of the neurotoxic effects of immunosuppressive drugs may be unrecognized hearing loss. In this study, our aim was to evaluate the hearing disorders in kidney transplant patients.

View Article and Find Full Text PDF

Introduction: Polycystic kidney disease (PKD) is responsible for 5%-10% of end-stage renal disease. We examined the relationship between renal and extrarenal findings, disease severity, and the level of consciousness of PKD patients.

Methods: Patients were asked to answer the questionnaire about PKD.

View Article and Find Full Text PDF

Introduction: Hemodialysis (HD) patients have increased risk for short-term adverse outcomes of COVID-19. However, complications and survival at the post-COVID-19 period have not been published extensively.

Methods: We conducted a national, multicenter observational study that included adult maintenance HD patients recovered from confirmed COVID-19.

View Article and Find Full Text PDF

Background: Although several renal biopsy registry reports have been published worldwide, there are no data on primary glomerular disease trends in Turkey.

Methods: Three thousand eight-hundred fifty-eight native kidney biopsy records were assessed in the Turkish Society of Nephrology Primary Glomerulopathy Working Group (TSN-GOLD) Registry. Secondary disease and transplant biopsies were not recorded in the registry.

View Article and Find Full Text PDF

Background/aim: This study aimed to investigate pregnancy frequency and evaluate the factors affecting live births in hemodialysis (HD) patients.

Materials And Methods: Female HD patients whose pregnancy was retrospectively reported between January 1, 2014, and December 31, 2019. The duration of HD, primary disease, whether the pregnancy resulted in abortion, stillbirth, or live birth, whether the HD duration was prolonged after diagnosing the pregnancy and whether it accompanied preeclampsia were recorded.

View Article and Find Full Text PDF

Introduction: Coronavirus related lockdown measures had a severe psychological toll. We investigated the effects of population-wide infection control measures on hemodialysis (HD) and oncology patients' mood statuses.

Methods: An electronic survey was used to collect data.

View Article and Find Full Text PDF

Background: Galactose-deficient IgA1 (Gd-IgA1) has an increased tendency to form immunocomplexes with IgG in the serum, contributing to IgAN pathogenesis by accumulating in the glomerular mesangium. Several studies showed that glomerular IgG deposition in IgAN is an important cause of mesangial proliferation and glomerular damage. This study aims to determine the association of the positivity of IgG and the intensity of IgG staining with a poor renal prognosis.

View Article and Find Full Text PDF

Introduction: There are many differences between hemodialysis (HD) and peritoneal dialysis (PD) treatments, including their impact on the psychological status of the patients. In this study, our aim was to compare the psychological statuses of HD and PD patients during the social isolation period due to the COVID-19 pandemic.

Methods: We conducted this cross-sectional study on adult HD and PD patients when the curfew measures were in effect.

View Article and Find Full Text PDF